Table 5. Association of APOE ε4 and ε2 with TN classification and stage in gastric cancer patients.
| Variable | Comparison of TN classification and stage according to presence of the APOEε4 allele |
Comparison of TN classification and stage according to presence of the APOEε2 allele |
||||
|---|---|---|---|---|---|---|
| ε4 allele present (N = 95) | ε4 allele not present (N = 455) | P-value | ε2 allele present (N = 91) | ε2 allele not present (N = 459) | P-value | |
| T classification | ||||||
| T1 | 3 (3.2%) | 17 (3.7%) | 0.38 | 5 (5.6%) | 15 (3.3%) | 0.63 |
| T2 | 12 (12.6%) | 63 (13.9%) | 9 (10.0%) | 66 (14.4%) | ||
| T3 | 54 (56.8%) | 214 (47.1%) | 49 (54.4%) | 219 (47.7%) | ||
| T4 | 26 (27.4%) | 160 (35.2%) | 27 (30.0%) | 159 (34.6%) | ||
| N classification | ||||||
| N0 | 23 (24.2%) | 97 (21.4%) | 0.96 | 17 (18.9%) | 103 (22.5%) | 0.78 |
| N1 | 11 (11.6%) | 71 (15.7%) | 19 (21.1%) | 63 (13.8%) | ||
| N2 | 22 (23.2%) | 105 (23.2%) | 20 (22.2%) | 107 (23.4%) | ||
| N3 | 39 (41.1%) | 180 (39.7%) | 34 (37.8%) | 185 (40.4%) | ||
| Stage | ||||||
| I | 8 (9.0%) | 33 (7.8%) | 0.59 | 6 (7.3%) | 35 (8.1%) | 0.23 |
| II | 23 (25.8%) | 111 (26.1%) | 25 (30.5%) | 109 (25.2%) | ||
| III | 56 (62.9%) | 259 (60.9%) | 51 (62.2%) | 264 (61.1%) | ||
| IV | 2 (2.2%) | 22 (5.2%) | 0 (0.0%) | 24 (5.6%) | ||
P-values result from a Wilcoxon rank sum test. Information was unavailable regarding T classification (1 gastric cancer patient), N classification (2 gastric cancer patients), and stage (36 gastric cancer patients). P-values of 0.0167 or lower were considered as statistically significant after applying a Bonferroni adjustment for multiple testing.